NCT00665834: CENTAURUS: two statins after acute coronary syndrome

Medicine Signal Editorial Desk
Updated 2026-10-10

Registry status when checked 2026-10-10Completed

Study: Queen's University's Canadian CENTAURUS protocol comparing rosuvastatin and atorvastatin after acute coronary syndrome. 1 2

Design and measurements: The phase IV registry records 18 actual participants. Its narrative describes early rosuvastatin 20 mg, delayed rosuvastatin 20 mg, and delayed atorvastatin 80 mg, using a short admission phase followed by three months of treatment. The primary comparison concerned the ApoB/ApoA ratio at 12 weeks; LDL cholesterol and inflammatory markers were additional measurements. The structured two-arm summary compresses the three-group narrative. 1 2

What is established: The record is completed, with a March 2016 update. No numerical lipid or clinical-event result was verified for this registration. Results from a larger similarly named program or the separate LUNAR trial cannot automatically be assigned to these 18 participants. 1 2

Sources

1. ClinicalTrials.gov — ClinicalTrials.gov — NCT00665834. Original study registration: sponsor, design, population, endpoints and dated history.Original study registration · Original record checked against the registry API. Checked 2026-10-10. Registration and current registry fields do not by themselves establish efficacy. Historical details in the article retain their stated date. Supplied note: ClinicalTrials.gov — NCT00665834. Original study registration: sponsor, design, population, endpoints and dated history.

2. ICH GCP — ICH GCP — readable reproduction of the sponsor-submitted ClinicalTrials.gov record. Supports the registration details quoted here; not an independent clinical-results publication.Cited supporting source · Link and description preserved from supplied research. Checked in supplied research dated 2026-10-10. Source description comes from supplied research; underlying page was not independently re-read for this update.